Try
PALVELLA THERAPEUTICS, INC.
PVLAUnited States
54 filed reports · 517 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
54 reports · Dec 2013 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 38 | 3,797 | Dec 2013 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 13 | 3,564 | Jun 2014 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 2 | 2 | Dec 2021 to Dec 2023 |
| Quarterly · 10-Q/ASEC EDGAR | 1 | 65 | Sep 2014 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 4, 2026 | 232 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 133 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 31, 2026 | 420 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 12, 2025 | 145 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 14, 2025 | 79 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 15, 2025 | 81 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 31, 2025 | 221 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 13, 2024 | 140 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 14, 2024 | 118 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 15, 2024 | 107 | Open |
| FY2023 | 10-K/A | Dec 31, 2023 | Apr 29, 2024 | 1 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 29, 2024 | 373 | Open |
Financial data
517 concepts · 7,428 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial506 concepts · 7,369 facts · May 2013 to Jul 2026
- Cash and cash equivalents at carrying value67 · Jun 2013 to Jun 2026
- Common stock par or stated value per share67 · Jun 2013 to Jun 2026
- Assets66 · Jun 2013 to Jun 2026
- Common stock shares authorized66 · Jun 2013 to Jun 2026
- Common stock shares issued66 · Jun 2013 to Jun 2026
- Common stock shares outstanding66 · Jun 2013 to Jun 2026
- Common stock value66 · Jun 2013 to Jun 2026
- Liabilities and stockholders equity66 · Jun 2013 to Jun 2026
- Net income loss66 · Sep 2013 to Jun 2026
- Operating income loss66 · Sep 2013 to Jun 2026
- Retained earnings accumulated deficit66 · Jun 2013 to Jun 2026
- General and administrative expense (US GAAP)65 · Sep 2013 to Jun 2026
- Operating expenses (US GAAP)65 · Sep 2013 to Jun 2026
- Comprehensive income net of tax63 · Dec 2013 to Jun 2026
- Liabilities63 · Jun 2013 to Jun 2026
- Liabilities current63 · Dec 2013 to Jun 2026
- Other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax63 · Dec 2013 to Jun 2026
- Other nonoperating income expense63 · Dec 2013 to Jun 2026
- Research and development expense63 · Dec 2013 to Jun 2026
- Stockholders equity (US GAAP)63 · Dec 2013 to Jun 2026
- Accumulated other comprehensive income loss net of tax61 · Dec 2013 to Jun 2026
- Assets current60 · Dec 2013 to Jun 2026
- Revenue58 · Sep 2013 to Sep 2024
- Share based compensation58 · Dec 2014 to Jun 2026
Geography7 concepts · 30 facts · Dec 2016 to Jun 2022
- Les Laboratoires Servier and Institut de Recherches Internationales Servier12 · Dec 2018 to Jun 2022
- Boston, Massachusetts8 · Dec 2018 to Mar 2020
- Freising, Germany4 · Dec 2018 to Mar 2020
- Germany2 · Dec 2016
- Lease and rental expense2 · Dec 2018 to Dec 2019
- Effective income tax rate reconciliation deductions1 · Dec 2016
- Hallbergmoos, Germany1 · Mar 2020
Product4 concepts · 29 facts · Dec 2013 to Sep 2020
- Revenue16 · Mar 2019 to Sep 2020
- Research and development arrangement with federal government customer funding to offset costs incurred8 · Dec 2013 to Dec 2016
- Seventh Research Framework Program (FP7 Agreement)3 · Dec 2014 to Dec 2016
- Revenue from grants2 · Dec 2013 to Dec 2014
Segments
59 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement geographicalsrt:StatementGeographicalAxis3 members · 21 facts
- Hallbergmoos Germany15 · Dec 2018 to Jun 2022
- Freising5 · Dec 2019 to Mar 2020
- Boston Massachusetts1 · Dec 2019
Product or servicesrt:ProductOrServiceAxis2 members · 16 facts
- Collaboration Revenue8 · Mar 2019 to Sep 2020
- Customer Revenue8 · Mar 2019 to Sep 2020
Product or serviceus-gaap:ProductOrServiceAxis2 members · 13 facts
- Bio Cluster M47 · Dec 2013 to Dec 2016
- Seventh Research Framework Program6 · Dec 2013 to Dec 2016
Statement geographicalus-gaap:StatementGeographicalAxis6 members · 9 facts
- Hallbergmoos Germany3 · Dec 2018
- Freising2 · Dec 2018
- AU1 · Dec 2016
- Boston Massachusetts1 · Dec 2018
- DE1 · Dec 2016
- US1 · Dec 2016
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 17, 2026) and refreshed every few hours.